



PROJECT PRAKASH

KEY LEARNING POINTS

Training: Hepatitis Induction Program Topic: Viral Hepatitis in Pregnancy Faculty: Ms. Anugrah Milton, HOD, OBG, RAKCON Period: 2021 - 2022 Attendees: In-Service Nurses

- ↓ Viral hepatitis is the commonest cause of jaundice in pregnancy.
- Hepatitis is mostly restricted to the ill-nourished mothers, living in unhygienic environment.
- There is also increased incidence of its affection in the pregnant state compared to the nonpregnant one.

	HAV	HBV		HCV		HDV		HEV
•	Severity of disease increases with advancing gestational age. Following complication s are seen; Preterm labour Placental abruption PROM (Premature rupture of membranes)	 Risk of transmission to fetus ranges from 10% in first trimester to as high as 90% in third trimester. Neonatal transmission mainly occurs at or around the time of delivery through mixing of maternal blood and genital secretions. Approximately 25% of the carrier neonate will die from cirrhosis or hepatic carcinoma. Screening All pregnant women should be screened for HBV infection at first antenatal visit. It should be repeated during the third trimester for "high risk" groups. 	•	Perinatal transmission is 3- 6%. Perinatal transmission (10– 40%) is high when viral load is high and presence of coinfection with HIV and HBV. Course of illness in pregnancy • HCV is usually milder than HAV and HBV, but it leads to chronic infection (70%) and cirrhosis (20%). • Probability of liver failure is 18%.	•	Perinatal transmission is known. Chronic carrier state is seen. Neonatal immunoprop hylaxis for HBV is almost effective against HDV. Acute infection with fulminant course results in high maternal mortality (2– 20%) due to hepatic failure.	•	May lead to fulminant hepatitis. Chronic carrier state is present. Perinatal transmission is uncommon. Maternal mortality following acute infection is high (15– 20%).

Viral Hepatitis in Pregnancy - Overview

Prognosis

Maternal:	Fetal:			
• There is increased incidence of postpartum haemorrhage, hepatic coma, renal failure, coagulopathy, infection and hepatorenal syndrome.	 There is increased incidence of abortion, preterm birth and intrauterine death leading to increased fetal wastage. Perinatal mortality is about 20–70%. 			

PRAKASH | PRogrammed Approach to Knowledge And Sensitization on Hepatitis





 All these lead to increased maternal morbidity and mortality. Medical termination of pregnancy does not alter the prognosis of the patient. 								
Prophylaxis								
 Pregnant Women HBV infection can be prevented by vaccination and the recombinant vaccine is safe in pregnancy. Pregnant woman who is seronegative, should have HB immunoglobulin (HBIG), 0.06 ml/kg IM, soon following exposure and a second dose after 1 month. 	 Infant All infants born to HBsAg positive mothers should have HBIG 0.5 ml IM within 12 hours of birth. Active immunization with HB vaccine (0.5 ml) is also given IM at a separate site at the same time schedule Breastfeeding is not contraindicated. 							
 Similar to HIV, perinatal transmission of HBV depends on maternal viral load. Lamivudine and HBIG are effective to reduce the transplacental transmission of HBV to the fetus. 								
 Management during Pregnancy There is no specific treatment. It is generally supportive. Rest: The patient should be put to bed rest. Isolation: The patient should be kept in isolation. Ensure adherence to infection prevention and control guidelines Nutrition: Diet rich in carbohydrate and protein. If the patient cannot tolerate oral feeding, 10% glucose may be given intravenously. Drugs: To prevent formation of the toxic nitrogenous compound from the bacterial flora of the gut, oral neomycin (1 gm to be given 6 hourly) is helpful. Lactulose (15–30 ml three times daily), reduces colonic ammonia absorption and it acts as an osmotic laxative. Hepatotoxic drugs should not be used. There is no place for termination of pregnancy. 								
 Prevention of complications: Hypokalemia, hypoglycemia and hypocalcemia are corrected by regular blood checkup. Hemorrhagic complications are managed by giving blood or fresh frozen plasma. Management during Labor: Hopatotoxic drugs should be avoided 								
 To administer vitamin K, 5 mg intramuscularly to raise the prothrombin level Prophylactic oxytocin is to be given. Hepatologists to be involved. Patient may need ICU management depending on liver function tests. 								
